Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06354465 · ClinicalTrials.gov registry record
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
A clinical trial of Opioid Use Disorder and Treatment Adherence and Compliance, sponsored by Lifespan.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06354465: Recruiting study of Opioid Use Disorder and Treatment Adherence and Compliance, sponsored by Lifespan.
NCT06354465 is a study of Opioid Use Disorder and Treatment Adherence and Compliance that is actively recruiting participants, run by Lifespan. The registered enrollment target is 25 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06354465, a study of Opioid Use Disorder and Treatment Adherence and Compliance, is actively recruiting participants, sponsored by Lifespan.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.
Conditions Studied
Study Locations (1)
Rhode Island
- Rhode Island Department of Corrections - Cranston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2024-07-01 |
What NCT06354465 shows while recruiting
NCT06354465 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06354465 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06354465 about?
NCT06354465 is a clinical study titled "Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews". This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a...
What is the current status of trial NCT06354465?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2023-07-01. Estimated completion is 2024-07-01.
What conditions does trial NCT06354465 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Treatment Adherence and Compliance, Criminal Justice.
Who is sponsoring clinical trial NCT06354465?
This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06354465 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06354465's enrollment target sits among peer trials
25 218th of 257 higher than 37 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI